NeoGenomics, Inc. is a company in the U.S. stock market and it is a holding in 61 U.S.-traded ETFs. NEO has around 15.7M shares in the U.S. ETF market. The largest ETF holder of NEO is the iShares Core S&P Small-Cap ETF (IJR), with approximately 6.24M shares. Investors may also find of interest that the ETF with the largest allocation to NEO stock is Innovator IBD Breakout Opportunities ETF (BOUT), with a portfolio weight of 3.58%. On average, U.S. ETFs allocate 0.37% of NEO to their portfolios.
Additionally, NEO is a favorite stock for Vanilla and Growth ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with NEO as a holding is the Alpha Architect U.S. Quantitative Momentum ETF (QMOM), with a return of 24.26%.